Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S01D
- Development stage
- Unknown
- Lead developer
- Wolwo Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
S01D is a novel, first-in-class small molecule therapeutic being developed for the treatment of drug-resistant pulmonary tuberculosis. Developed by Zhejiang Wolwo Bio-Pharmaceutical (Wolwo Pharma) through its subsidiary Zhejiang Wolwo Yifang Pharmaceutical, S01D is a Class 1 chemical new drug featuring a unique tetracyclic chemical structure (6,5,7,6-tetracyclic derivative) and a novel mechanism of action. Non-clinical studies have demonstrated that S01D possesses potent anti-Mycobacterium tuberculosis activity. In October 2026, the National Medical Products Administration (NMPA) of China approved the clinical trial application (IND) for S01D tablets, allowing the initiation of Phase I, II, and III clinical trials in adult patients with drug-resistant pulmonary tuberculosis.
Beyond the preview
Go deeper on S01D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S01D.